Literature DB >> 70062

Cellular distrubtion, purification, and molecular nature of human Ia antigens.

D Snary, C J Barnstable, W F Bodmer, P N Goodfellow, M J Crumpton.   

Abstract

Human Ia antigens were extensively purified (1390-fold increase in specific activity) in 32% yield from BRI 8 cells, a lymphoblastoid B-cell line. Purification was monitored by using allogeneic antisera arising by foetal-maternal stimulation. The product, a glycoprotein fraction, contained the Ia antigens, the HLA-A and -B antigens, and a glycoprotein of unknown function. The glycoprotein fraction was composed of four glycosylated polypeptides with molecular weights of 43,000, 39,000, 33,000, and 28,000, and beta2-microglobulin; no polypeptide was linked to another by disulphide bridges. The A and B antigens only were absorbed by antibody against beta2-microglobulin. The Ia antigens comprised one each of the 33,000 and 28,000 molecular weight glycosylated polypeptides noncovalently linked together. Thus, only these chains were absorbed by xenogeneic anti-Ia antisera and were cross-linked by dimethyl-3-3'-dithiobispropionimidate dihydrochloride. The dimeric molecule bound deoxycholate (0.26 g/g of protein) and, when solubilized in deoxycholate, has a molecular weight of 77,000. The Ia allo- and xeno-antigenic activities were labile to heating and proteolysis and are probably determined by the polypeptide structure. Xenogeneic specific anti-Ia antisera were raised in rabbits and mice by immunizing with the glycoprotein fraction. These antisera reacted with B lymphocytes and monocytes but not T lymphocytes and fibroblasts. Their Fab fragments blocked the cytotoxicity of the allogeneic antisera for B lymphocytes and were potent inhibitors of the mixed lymphocyte reaction.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 70062     DOI: 10.1111/j.1365-3083.1977.tb02101.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  29 in total

1.  Expression of ia antigens by murine keratinizing epithelial langerhans cells.

Authors:  G Rowden; T M Phillips; T L Delovitch
Journal:  Immunogenetics       Date:  1978-12       Impact factor: 2.846

2.  Relation between T cell number and epithelial HLA class II expression quantified by image analysis in normal and inflamed human gastric mucosa.

Authors:  K Valnes; H S Huitfeldt; P Brandtzaeg
Journal:  Gut       Date:  1990-06       Impact factor: 23.059

3.  Biochemical characterization of the T-cell alloantigen RT-6.2.

Authors:  H G Thiele; F Koch; A Hamann; R Arndt
Journal:  Immunology       Date:  1986-10       Impact factor: 7.397

4.  Modulation of Fc receptors on human peripheral blood lymphocytes by antisera against beta 2 microglobulin, Ia or immunoglobulin.

Authors:  G Sarmay; A Sanderson; J Ivanyi
Journal:  Immunology       Date:  1979-02       Impact factor: 7.397

5.  Rabbit antiserum to human thymocyte membranes: specificity for normal and malignant T-lymphocytes.

Authors:  N Gross; C Bron
Journal:  Clin Exp Immunol       Date:  1978-08       Impact factor: 4.330

6.  Lactoferrin acts on Ia-like antigen-positive subpopulations of human monocytes to inhibit production of colony stimulatory activity in vitro.

Authors:  H E Broxmeyer
Journal:  J Clin Invest       Date:  1979-12       Impact factor: 14.808

7.  Monoclonal antibodies that recognize discrete forms of tubulin.

Authors:  I Gozes; C J Barnstable
Journal:  Proc Natl Acad Sci U S A       Date:  1982-04       Impact factor: 11.205

8.  Surface markers of resting and activated human T cells. Functional implications and experimental limits.

Authors:  M C Mingari; A Moretta; G Pantaleo; L Moretta
Journal:  Springer Semin Immunopathol       Date:  1982

9.  A clinical trial of fibroblast transplantation for the treatment of mucopolysaccharidoses.

Authors:  D A Gibbs; E Spellacy; R Tompkins; R W Watts; J F Mowbray
Journal:  J Inherit Metab Dis       Date:  1983       Impact factor: 4.982

10.  Different HLA-D associations in adult and juvenile rheumatoid arthritis.

Authors:  P Stastny; C W Fink
Journal:  J Clin Invest       Date:  1979-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.